Two more domestic innovative devices have been approved: the total number has reached 366, making them more precise in treating aneurysms and pulmonary embolism

  Every time the National Medical Products Administration approves new medical devices, especially those that are domestically produced and independently developed, medical device enthusiasts feel particularly encouraged - this is not only a technological breakthrough, but also means that more patients can receive treatment faster and more safely.

On August 22nd, two more domestic innovative medical devices obtained the "pass to market" :

One is a stent for assisted embolization of cerebral aneurysms, and the other is a stent system for thrombectomy of acute pulmonary embolism.

One of them focuses on "precise repair", and the other emphasizes "rapid life-saving". Both are truly excellent tools that can change the current clinical situation.

So far, the number of innovative medical devices approved for marketing in our country has reached 366 - domestic medical equipment is quietly rising.

Let's start with the first product - the TaminoVIA® intracranial aneurysm auxiliary embolization stent from Jiangsu Changyida.

It is used to deal with "brain aneurysms". You can understand a cerebral aneurysm as a "small blood bubble" bulging on the wall of a cerebral blood vessel. Once it ruptured, it can cause cerebral hemorrhage, which is extremely dangerous.

In the past, when placing stents in, the most feared situations were inaccurate placement, unstable adhesion, or blocking normal blood flow.

This stand is made with monofilament weaving technology, which can be understood as precisely woven from a special metal wire. The overall structure is very smooth and easy to place.

Both ends of it are designed as "flared mouths", which can well adhere to the blood vessel wall and seal the tumor opening. This design enables the stent to better adhere to the blood vessel wall and prevent displacement.

At the same time, it does not affect the normal vascular branches around.

Even more impressive is that this stand achieves full-segment visualization. It is clearly visible throughout the X-ray process, with the entire segment being developed. This enables doctors to adjust the position in real time. Even if it is not placed properly, it can be retracted and re-placed - significantly enhancing the safety and accuracy of the surgery. This is like adding wings to a tiger for complex intracranial surgeries.

Clinical data show that the high-density mesh structure of this stent forms an effective blood flow orientation at the neck of the aneurysm, which can not only close the aneurysm opening but also protect the branch vessels, significantly reducing the risk of vascular injury.

It has a wide diameter coverage and is compatible with the current mainstream microcatheters, capable of reaching more distant and thinner vascular areas in the brain, thus providing more patients with complex location aneurysms with the opportunity for minimally invasive treatment.

The second product is the TwiFlow™ pulmonary artery thrombectomy stent system from Morningside Medical, which is specifically designed to treat acute pulmonary embolism.

Pulmonary embolism is a very dangerous disease. In simple terms, it means "a blood clot blocks the pulmonary artery", preventing blood flow and potentially leading to cardiac arrest or even death. The previous treatment methods mainly involved the use of thrombolytic drugs, but this approach carried the risk of bleeding and had a relatively long recovery time.

The emergence of the TwiFlow™ system has completely changed this situation. It is designed via the femoral vein route, entering the body through the vein at the root of the thigh and reaching the main pulmonary artery and its branches to remove the thrombus.

This system does not require thrombolytic drugs for assistance: direct physical thrombectomy reduces the risk of postoperative bleeding. According to clinical data, the risk of postoperative bleeding has been reduced by more than 40%. Its large-diameter design can quickly capture and remove blood clots, shortening the patient's recovery period to one third of that of traditional regimens. The preoperative preparation time has been compressed to within 15 minutes, significantly enhancing the efficiency of emergency rescue.

For patients with acute extensive pulmonary embolism, time is life. The TwiFlow™ system, with its highly efficient thrombus capture capability, can save more lives at critical moments.

Traditional treatments either involve thrombolysis with medication, but the drawback is that it is prone to causing massive bleeding, or thoracotomy, which is extremely invasive.

This thrombectomy system is like a "minimally invasive vacuum cleaner" : it is punctured through the thigh vein and delivered all the way to the pulmonary artery, directly using a large-diameter device to "retrieve" or "suck out" the thrombus. It does not require thrombolytic drugs at all, so the risk of postoperative bleeding for patients is reduced by more than 40%, and the recovery time is also shortened to one third of the original.

The most commendable aspect is that it has compressed the preoperative preparation time to within 15 minutes - for emergency rescue, every minute saved could potentially save an additional life.

You might be wondering: What exactly do these innovations mean to us ordinary people?

It means safer, more accurate and faster treatment options.

For instance, patients with cerebral aneurysms can, in the future, have a greater chance of preserving their functions and improving their quality of life while reducing the risk of nerve damage. For patients with pulmonary embolism, especially the elderly, those at risk of bleeding or those who cannot receive thrombolysis, there is now an additional rapid and minimally invasive life-saving option.

It is worth mentioning that neither of these two enterprises emerged out of nowhere.

Jiangsu Changyida is one of the very few domestic enterprises that comprehensively cover the full range of products for stroke (stroke) hemorrhage and ischemia. Although Morningside Medical was only established in 2021, it has quietly laid out over 30 patents in the field of cardiopulmonary intervention.

Domestic medical innovation is now entering a deep-water zone - not just remaining at imitation, but truly addressing clinical pain points and saving lives.

The advancement of technology is ultimately for the benefit of people.

The approval of each new device is the result of years of hard work by countless researchers and clinical experts, as well as the rigorous argumentation and accelerated promotion by regulatory review departments.

We look forward to the emergence of more such domestic innovative medical products that can "keep pace with" or even "lead" the world

Because good technology should not be monopolized. Good treatment should be within easy reach.

Note: The above content is for reference only and does not constitute investment advice. The relevant interpretations of official policies in this article only represent the views of this platform. The content is subject to official documents.